AI empowers healthier lifestyles through personalized wellness, exercise, nutrition, and preventive care for a happier future. (AI generated image.)
“Our goal is to bring genetic testing down from its pedestal and make it an everyday tool that everyone can use easily, conveniently, and affordably.”
In a recent interview, Dr. Yin Ye, CEO of BGI Group, described a structural shift underway in genomics: the defining challenge is no longer primarily how to sequence faster or cheaper, but how to turn vast genomic data into reliable, usable understanding. In his view, artificial intelligence is changing genetic testing in two connected ways - by dramatically improving interpretation efficiency and by expanding the range of biological questions that testing can answer.
For years, the sequencing industry concentrated on “reading” DNA: accurately decoding the ATCG sequence and lowering the cost per genome. That capability is now mature enough that a new bottleneck stands out - interpretation. As sequencing becomes more accessible, laboratories and clinicians face an explosion of data, while the capacity to interpret results with consistency and clinical relevance has not scaled at the same pace. Dr. Yin emphasized that the next phase of progress depends on moving from generating data to understanding it - quickly, reproducibly, and in a way that can support real clinical and public health workflows.
BGI’s approach is to pair foundation models with application-layer tools. In 2025, BGI Research released Genos, the world’s first 10-billion-parameter open-source Human-Centric genomic foundation model, trained on 636 high-quality genomes representing diverse populations. Dr. Yin highlighted Genos’ ability to improve analysis of non-coding regions - parts of the genome that have often been underused because they are harder to interpret, even though they influence many regulatory mechanisms in human biology. By using long-context modeling, Genos is designed to examine long genomic spans and identify signals at single-base resolution, enabling more systematic exploration of regions that were previously treated as “unknowns” in routine analysis.
Building on BGI Group’s underlying capability, BGI Genomics introduced GeneT, a general-purpose AI agent in the field of genetic testing. Dr. Yin pointed to clinical genetic counseling as a clear example of why such tools matter: the field faces a persistent shortage of specialized professionals, and interpretation workloads can become a limiting factor even when sequencing is readily available. By connecting curated knowledge bases with sequencing data, GeneT is designed to assist in generating standardized interpretive content and report drafts, aiming to improve throughput and reduce time-to-insight.
Dr. Yin also stressed that technical progress must be measured by real-world impact. Screening and prevention for digestive system cancers illustrates the gap between what medicine can do and what systems can deliver. Many cancer deaths are associated with modifiable risk factors, yet screening adoption is often constrained by tangible barriers: cost, discomfort, and uneven distribution of medical resources. Endoscopy, for example, is effective but invasive, and reluctance among high-risk populations can sharply limit participation.
To reduce friction and increase access, BGI launched a large public welfare initiative in Harbin City, China, covering 2.4 million residents. The program uses BGI’s stool DNA methylation testing technology and is designed around convenience: residents collect samples at home, while community health institutions manage logistics and centralized testing. Dr. Yin described the goal in everyday terms: “to make testing as simple as sending and receiving a package.” By July 2025, cumulative appointments exceeded 800,000 - a figure the program presents as evidence that large-scale early cancer screening is feasible when the pathway is convenient and costs are controllable.
BGI’s product development in this area continues with its latest blood-based test service, which requires 20 mL of peripheral blood to assess risk across five digestive system malignancies: colorectal, gastric, esophageal, liver, and pancreatic cancers. According to clinical validation data shared in the interview, the test achieved an overall sensitivity of 78.1% and specificity of 98.8%. From stool-based testing to multi-cancer blood testing, BGI framed the direction as consistent—iterating toward higher accessibility and easier adoption without compromising analytical performance.
Scaling such programs requires more than assays; it requires industrial-grade delivery. Dr. Yin highlighted BGI’s ongoing investment in automation, including the SIRO AI-Powered Localized Solution for High-Throughput Genetic Testing, which supports end-to-end automation from sample receipt to report generation. By compressing reporting time and standardizing workflows, systems like SIRO are positioned as the operational backbone that enables genetic testing to function as public health infrastructure rather than a niche clinical service.
The interview also addressed preparedness for infectious disease threats. Events such as chikungunya cases and Nipah-related outbreaks underscore the importance of rapid, accurate pathogen identification. BGI described its response capability as grounded in metagenomic sequencing, rapid testing products, and an integrated technology stack spanning sequencing platforms, reagents, and algorithmic models - supporting faster deployment and localized capacity building when outbreaks emerge.
Internationally, BGI emphasized a collaboration model focused on building local capability, not merely supplying products. As Dr. Yin noted, in April 2024 BGI Genomics established a clinical molecular testing laboratory in Uruguay, and in February 2026, BGI Group signed a Memorandum of Understanding with Uruguay's leading national research institution Clemente Estable Institute of Biological Research (IIBCE) to further deepen collaboration in genomics and cancer prevention and control. The stated aim is to translate technological solutions into durable public health capacity that can serve local needs.
Looking ahead, Dr. Yin described two broad directions for the field: genomics becoming a routine component of health management as costs fall, and sequencing continuing to act as the essential “reading” layer that supports biomanufacturing fields such as synthetic biology and cellular agriculture. Across these domains, BGI’s central message is that AI is not only accelerating analysis—it is expanding what genetic testing can reliably interpret, and making it easier to deliver at scale.
The full interview text is available here: https://m.eeo.com.cn/2026/0212/792315.shtml